Literature DB >> 7720438

Safety of urgent restorative proctocolectomy with ileal pouch-anal anastomosis for fulminant colitis.

Y Ziv1, V W Fazio, J M Church, J W Milsom, T K Schroeder.   

Abstract

PURPOSE: Subtotal colectomy with ileostomy is the operation of choice for patients with fulminant colitis. Restorative proctocolectomy (RPC) with ileal pouch-anal anastomosis (IPAA) is preferred for patients who undergo elective surgery for ulcerative colitis. We retrospectively evaluated the safety of RPC with IPAA in patients with a moderate form of fulminant colitis.
METHODS: A chart review of 737 patients who underwent RPC with IPAA for ulcerative and indeterminate colitis from 1983 through 1992 was performed. Moderate fulminant colitis was defined as acute disease requiring hospitalization and parenteral steroid therapy, but without hypotension (systolic blood pressure, < 100 mmHg), tachycardia (> 120 beats/min), or megacolon.
RESULTS: Twelve patients with moderate fulminant colitis underwent urgent surgery (1.6 percent). They had been treated preoperatively for 5.1 +/- 2.3 days with intravenous high-dose steroids, total parenteral nutrition, and antibiotics. These patients had a shorter length of disease (P = 0.01), lower hemoglobin, hematocrit, and albumin (P = 0.001), and higher temperature (P = 0.002) and leukocyte count (P = 0.007) than patients undergoing elective surgery. No early septic complications occurred, although perianal abscess occurred in one patient and pouch-anal fistula in another patient, 13 and 14 months after surgery, respectively.
CONCLUSION: In carefully selected, hemodynamically stable patients with fulminant colitis and without megacolon, RPC with IPAA can be safely performed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7720438     DOI: 10.1007/bf02054219

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  9 in total

1.  Ileal pouch anal anastomosis without ileal diversion.

Authors:  H J Sugerman; E L Sugerman; J G Meador; H H Newsome; J M Kellum; E J DeMaria
Journal:  Ann Surg       Date:  2000-10       Impact factor: 12.969

2.  Should ileoanal pouch surgery be staged for patients with mucosal ulcerative colitis on immunosuppressives?

Authors:  Oded Zmora; Marat Khaikin; Turab Pishori; Alon Pikarsky; Adam Dinnewitzer; Eric G Weiss; Juan J Nogueras; Steven D Wexner
Journal:  Int J Colorectal Dis       Date:  2006-08-24       Impact factor: 2.571

3.  Management of acute colitis and toxic megacolon.

Authors:  Scott A Strong
Journal:  Clin Colon Rectal Surg       Date:  2010-12

4.  Long-Term Outcome of IPAA in Patients Presenting with Fulminant Ulcerative Colitis: A Matched Cohort Study.

Authors:  Geoffrey S Fasen; T K Pandian; Emily S Pavey; Eric J Dozois; Sarah Y Boostrom
Journal:  World J Surg       Date:  2015-10       Impact factor: 3.352

5.  The incidence and outcome of pelvic sepsis following handsewn and stapled ileal pouch anal anastomoses.

Authors:  T Fukushima; A Sugita; K Koganei; M Shinozaki
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

6.  Surgical management of acute colitis and toxic megacolon.

Authors:  Tracey D Arnell
Journal:  Clin Colon Rectal Surg       Date:  2004-02

7.  Complications after ileal pouch-anal anastomosis in Korean patients with ulcerative colitis.

Authors:  Seung-Bum Ryoo; Heung-Kwon Oh; Eon Chul Han; Heon-Kyun Ha; Sang Hui Moon; Eun Kyung Choe; Kyu Joo Park
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

8.  Endoscopic treatment for repeated arterial bleeding with ulcerative colitis.

Authors:  Tadayuki Oshima; Takashi Joh; Hiromi Kataoka; Makoto Sasaki; Fumitaka Fujita; Shozo Togawa; Tsuneya Wada; Etsuko Iio; Makoto Itoh
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.487

9.  Primary ileo-anal pouch anastomosis in patients with acute ulcerative colitis.

Authors:  Jacek Hermann; Jacek Szmeja; Tomasz Kościński; Wiktor Meissner; Michał Drews
Journal:  Arch Med Sci       Date:  2013-02-10       Impact factor: 3.318

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.